Michael Garitty, MD
Orthopaedic Surgery · Lake Charles, LANPI 1962815332
Payments from drug & device makers
What this record shows
This record is dominated by education: $22,320 of the $30,296 with a category attached, or 73.7%. Smith+Nephew accounts for 71.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $12,323 and has fallen 94.5% since, to $678 in 2025.
Across 86 payments — averaging $352.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$22K
- Stryker$7K
- Peerless Surgical Inc.$820
- Zimmer Biomet$266
- Orthalign Inc$119
- Pacira Therapeutics, Inc.$113
- plus $73 from 2 others
What the payments were for
- Travel & lodging$4,80616%
- Food & beverage$3,17010%
- Education$22,32074%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 4 | $21,521 |
| Stryker(2 entities) | 75 | $7,385 |
| Peerless Surgical Inc. | 1 | $820 |
| Zimmer Biomet | 2 | $266 |
| Orthalign Inc | 1 | $119 |
| Pacira Therapeutics, Inc. | 1 | $113 |
| Curonix LLC | 1 | $53 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$5,658
- Persona$150
- ORTHALIGN PLUS$119
- Persona Revision$117
- Zilretta$113
How this compares
$30,296 in reported general payments places this provider in the 85th percentile of 286 orthopaedic surgery providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 178 | $2,037 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 163 | $1,150 |
| Tramadol Hcl | 191 | $907 |
| Mupirocin | 112 | $865 |
| Ondansetron Hcl | 93 | $639 |
| Cefadroxil | 86 | $539 |
| Methylprednisolone | 30 | $190 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $127 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $80 |
| Meloxicam | 21 | $69 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Lake Charles
- Thomas AxelradLake Charles$75K
- James JacksonLake Charles$26K
- Christopher HarrodBaton Rouge$3M
- Vinod DasaKenner$1.9M
- Pierce NunleyShreveport$1.8M
- Jorge IsazaBaton Rouge$1.2M
- Neil MakiThibodaux$620K
- Robert ZuraNew Orleans$597K
- Kevin McCarthyBaton Rouge$594K
- Timmothy RandellAlexandria$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.